Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment

References

• Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997; 51: 692–697
   PubMed Web of Science ®Google Scholar
• Rodger A J, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582–587
   PubMed Web of Science ®Google Scholar
• Hser Y I, Hoffman V, Grella C E, Anglin M D. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58: 503–508
   PubMed Web of Science ®Google Scholar
• Chander G, Sulkowski M S, Jenckes M W, Torbenson M S, Herlong H F, Bass E B, Gebo K A. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S135–S144
   PubMed Web of Science ®Google Scholar
• National Institute of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997; 26: 2S–10S
   Google Scholar
• Dore G J, Thomas D L. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005; 25: 18–32
   PubMed Web of Science ®Google Scholar
• Edlin B R, Seal K H, Lorvick J, Kral A H, Ciccarone D H, Moore L D, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med 2001; 345: 211–215
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443–451
   PubMed Web of Science ®Google Scholar
• Sylvestre D L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117–123
   PubMed Web of Science ®Google Scholar
• Hallinan R, Byrne A, Amin J, Dore G J. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005; 20: 1082–1086
   PubMed Web of Science ®Google Scholar
• Batey R (2004) Cost of addiction – Hepatitis C. Annual Scientific Meeting of The Royal Australasian College of Physicians. 2004. Canberra
   Google Scholar
• Davis G L, Rodrigue J R. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345: 215–217
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Watson K, Locarnini S, Desmond P. Role of alcohol in the progression of liver disease caused by hepatitis c virus infection. Hepatology 1998; 27: 1730–1735
   PubMed Web of Science ®Google Scholar
• Peters M G, Terrault N A. Alcohol use and hepatitis C. Hepatology 2002; 36: S220–S225
   PubMed Web of Science ®Google Scholar
• What do I need to know about hepatitis C. Gastroenterological Society of Australia. 1997
   Google Scholar
• Joseph H, Appel P. Alcoholism and methadone treatment: consequences for the patient and program. Am J Drug Alcohol Abuse 1985; 11: 37–53
   PubMed Web of Science ®Google Scholar
• Hillebrand J, Marsden J, Finch E, Strang J. Excessive alcohol consumption and drinking expectations among clients in methadone maintenance. J Subst Abuse Treat 2001; 21: 155–160
   PubMed Web of Science ®Google Scholar
• McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 1997; 96: 1007–1014
   Google Scholar
• Cohen M, Korts D, Hanbury R, Sturiano V, Jackson G, Stimmel B. The effect of alcoholism in methadone-maintained persons on productive activity: a randomized control trial. Alcohol Clin Exp Res 1982; 6: 358–361
   PubMedGoogle Scholar
• Stimmel B, Cohen M, Sturiano V, Hanbury R, Korts D, Jackson G. Is treatment for alcoholism effective in persons on methadone maintenance?. Am J Psychiatry 1983; 140: 862–866
   PubMed Web of Science ®Google Scholar
• Dieperink E, Willenbring M, Ho S B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867–876
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S–10S
   Web of Science ®Google Scholar
• Schaefer M, Schwaiger M, Garkisch A S, Pich M, Hinzpeter A, Uebelhack R, Heinz A, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793–798
   PubMed Web of Science ®Google Scholar
• Van Thiel D, Friedlander L, Molloy P, Fagiuoli S, Kania R, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7: 165–168
   PubMed Web of Science ®Google Scholar
• Aitken C K, Kerger M, Crofts N. Peer-delivered hepatitis C testing and counselling: a means of improving the health of injecting drug users. Drug Alcohol Rev 2002; 21: 33–37
   PubMed Web of Science ®Google Scholar
• C-change: the report of the enquiry into hepatitis C related discrimination: Anti-Discrimination Board of NSW; 2001 November.
   Google Scholar
• Kaldor J M, Plant A J, Thompson S C, Longbottom H, Rowbottom J. The incidence of hepatitis B infection in Australia: an epidemiological review.[see comment]. Med J Aus 1996; 165: 322–326
   PubMedGoogle Scholar
• Day C, White B, Ross J, Dolan K. Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney. Aus NZ J Public Health 2003; 27
   PubMedGoogle Scholar
• Crofts N, Aitken C. Incidence of blood bourne virus infection and risk behaviours in a cohort of injecting drug users in Victoria 1990 – 1995. Med J Aus 1997; 167: 368–371
   Google Scholar
• Weltman M D, Brotodihardjo A, Crewe E B, Farrell G C, Bilous M, Grierson J M, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39–45
   PubMed Web of Science ®Google Scholar
• Recommendations on hepatitis B immunisation. Health. National Health and Medical Research Council. 1996, editor
   Google Scholar
• Anderson B, Bodsworth N J, Rohrsheim R A, Donovan B J. Hepatitis B virus infection and vaccination status of high risk people in Sydney: 1982 and 1991. Med J Aus 1994; 161: 368–371
   PubMed Web of Science ®Google Scholar
• Loxley W. Doing the possible: harm reduction, injecting drug use and blood borne viral infections in Australia. Int J Drug Policy 2000; 11: 407–416
   PubMedGoogle Scholar
• Bush K, Kivlahan D R, McDonell M B, Fihn S D, Bradley K A. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158: 1789–1795
   PubMed Web of Science ®Google Scholar
• Bradley K, Bush K, Epler A, Dobie D, Davis T, Sporleder J, Maynard C, et al. Two brief alcohol-screening tests from the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient population. Arch Intern Med 2003; 163: 821–829
   PubMed Web of Science ®Google Scholar
• Lovibond P F, Lovibond S H. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 1995; 33: 335–343
   PubMed Web of Science ®Google Scholar
• Antony M, Bieling P, Cox B, Enns M, Swinson R. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales (DASS) in clinical groups and a community sample. Psycholog Assess 1998; 10: 176–181
   Web of Science ®Google Scholar
• Saunders J B, Aasland O G, Babor T F, de la Fuente J R, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption - II. Addiction 1993; 88: 791–804
   PubMed Web of Science ®Google Scholar
• Skipsey K, Burleson J A, Kranzler H R. Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients. Drug Alcohol Depend 1997; 45: 157–163
   PubMed Web of Science ®Google Scholar
• Gomel M, Saunders J, Burns L, Hardcastle D, Sumich M. Dissemination of early intervention for harmful alcohol consumption in general practice. Health Promot J Aus 1994; 4: 65–69
   Google Scholar
• Proude E M, Conigrave K M, Haber P S. Effectiveness of skills-based training using the Drink-less package to increase family practitioner confidence in intervening for alcohol use disorders. Biomed Central Medical Education 2006; 6: 8–13
   PubMedGoogle Scholar
• Proude E M, Conigrave K M, Haber P S. The Drink-Less Program. Report to NSW Roads and Traffic Authority on the update and review of the alcohol interlock brief intervention program. The University of Sydney, Sydney 2006
   Google Scholar
• Bush K, Kivlahan D R, McDonell M B, Fihn S D, Bradley K A. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158: 1789–1795
   PubMed Web of Science ®Google Scholar
• Skipsey K, Burleson J A, Kranzler H R. Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients. Drug Alcohol Depend 1997; 45: 157–163
   PubMed Web of Science ®Google Scholar
• Lovibond S, Lovibond P. Manual for the Depression Anxiety Stress Scales. 2nd ed. Psychology Foundation, Sydney 1995
   Google Scholar
• Statistics on drug use in Australia 2004. Welfare AIoHa. 2005, editor
   Google Scholar
• Gossop M, Browne N, Stewart D, Marsden J. Alcohol use outcomes and heavy drinking at 4 – 5 years among a treatment sample of drug misusers. J Subst Abuse Treat 2003; 25: 135–143
   PubMed Web of Science ®Google Scholar
• Wiley T E, McCarthy M, Breidi L, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805–809
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Watson K J, Locarnini S A, Desmond P V. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730–1735
   PubMed Web of Science ®Google Scholar
• Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717–1722
   PubMedGoogle Scholar
• Caudai C, Padula M G, Bastianoni I, Valensin P E, Shyamala V, Han J, Boggiano C A, et al. Antibody testing and RT-PCR results in hepatitis C virus (HCV) infection: HCV-RNA detection in PBMC of plasma viremia-negative HCV-seropositive persons. Infection 1998; 26: 151–154
   PubMedGoogle Scholar
• Strasser S I, Watson K J, Lee C S, Coghlan P J, Desmond P V. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection. Med J Aust 1995; 162: 355–358
   PubMed Web of Science ®Google Scholar
• Dean A J, Bell J, Christie M J, Mattick R P. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry 2004; 19: 510–513
   PubMed Web of Science ®Google Scholar
• McCoy C B, Metsch L R, Chitwood D D, Miles C. Drug use and barriers to use of health care services. Subst Use Misuse 2001; 36: 789–806
   PubMed Web of Science ®Google Scholar
• Walley A Y, White M C, Kushel M B, Song Y S, Tulsky J P. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005; 28: 181–187
   PubMed Web of Science ®Google Scholar
• Hocking J, Crofts N, Aitken C, McDonald M. Epidemiology of the hepatitis C virus among injecting drug users. Hepatitis C: An Australian perspective, N Crofts, G Dore, S Locarnini. IP Communications, Melbourne 2001; 260–295
   Google Scholar